Vaishali Pharma
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Feb 13 (Reuters) - Vaishali Pharma Ltd VAIH.NS:
VAISHALI PHARMA - APPROVED ISSUE OF SHARES OF UP TO 122.5 MILLION RUPEES
Source text: [ID:]
Further company coverage: VAIH.NS
(([email protected];))
Feb 13 (Reuters) - Vaishali Pharma Ltd VAIH.NS:
VAISHALI PHARMA - APPROVED ISSUE OF SHARES OF UP TO 122.5 MILLION RUPEES
Source text: [ID:]
Further company coverage: VAIH.NS
(([email protected];))
Oct 3 (Reuters) - Vaishali Pharma Ltd VAIH.NS:
APPROVED PROPOSAL FOR FURTHER EXPANSION AND ACQUISITION
Source text for Eikon: ID:nNSE4pNnhQ
Further company coverage: VAIH.NS
(([email protected];;))
Oct 3 (Reuters) - Vaishali Pharma Ltd VAIH.NS:
APPROVED PROPOSAL FOR FURTHER EXPANSION AND ACQUISITION
Source text for Eikon: ID:nNSE4pNnhQ
Further company coverage: VAIH.NS
(([email protected];;))
Sept 24 (Reuters) - Vaishali Pharma Ltd VAIH.NS:
PLANS MERGER, ACQUISITION FOR GROWTH IN GLOBAL PHARMACEUTICAL MARKET
Source text for Eikon: ID:nNSE4gjbqx
Further company coverage: VAIH.NS
(([email protected];;))
Sept 24 (Reuters) - Vaishali Pharma Ltd VAIH.NS:
PLANS MERGER, ACQUISITION FOR GROWTH IN GLOBAL PHARMACEUTICAL MARKET
Source text for Eikon: ID:nNSE4gjbqx
Further company coverage: VAIH.NS
(([email protected];;))
** Shares of Vaishali Pharma VAIH.NS rise ~2% after jumping as much as 3.2% earlier in the session
** Drugmaker's board approves 1-to-5 stock split
** Approves issue of bonus shares in 1:1 ratio
** VAIH on track for fourth straight session of gains
** Trading vol is nearly 5x the 30-day avg
** Stock up 6% YTD
(Reporting by Hritam Mukherjee in Bengaluru)
(([email protected];))
** Shares of Vaishali Pharma VAIH.NS rise ~2% after jumping as much as 3.2% earlier in the session
** Drugmaker's board approves 1-to-5 stock split
** Approves issue of bonus shares in 1:1 ratio
** VAIH on track for fourth straight session of gains
** Trading vol is nearly 5x the 30-day avg
** Stock up 6% YTD
(Reporting by Hritam Mukherjee in Bengaluru)
(([email protected];))
Aug 28 (Reuters) - Vaishali Pharma Ltd VAIH.NS:
VAISHALI PHARMA - APPROVED BONUS ISSUE OF SHARES AT RATIO OF 1 : 1
VAISHALI PHARMA LTD - SUB-DIVISION OF 1 SHARE INTO 5 SHARES
Source text for Eikon: [ID:]
Further company coverage: VAIH.NS
(([email protected];))
Aug 28 (Reuters) - Vaishali Pharma Ltd VAIH.NS:
VAISHALI PHARMA - APPROVED BONUS ISSUE OF SHARES AT RATIO OF 1 : 1
VAISHALI PHARMA LTD - SUB-DIVISION OF 1 SHARE INTO 5 SHARES
Source text for Eikon: [ID:]
Further company coverage: VAIH.NS
(([email protected];))
Vaishali Pharma Ltd VAIH.NS:
VAISHALI PHARMA LTD- GETS GLOBAL PRODUCT REGISTRATIONS, SEE REVENUE BOOST BY 100 MILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: VAIH.NS
Vaishali Pharma Ltd VAIH.NS:
VAISHALI PHARMA LTD- GETS GLOBAL PRODUCT REGISTRATIONS, SEE REVENUE BOOST BY 100 MILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: VAIH.NS
Nov 28 (Reuters) - Vaishali Pharma Ltd VAIH.NS:
RECEIVED NEW ORDER WORTH $800,000
EXECUTION OF ENTIRE ORDER IS PLANNED FOR FY24
Source text for Eikon: [ID:]
Further company coverage: VAIH.NS
(([email protected];))
Nov 28 (Reuters) - Vaishali Pharma Ltd VAIH.NS:
RECEIVED NEW ORDER WORTH $800,000
EXECUTION OF ENTIRE ORDER IS PLANNED FOR FY24
Source text for Eikon: [ID:]
Further company coverage: VAIH.NS
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Vaishali Pharma do?
Vaishali Pharma Limited is a Mumbai-based pharmaceutical company that markets a range of products, including active pharmaceutical ingredients. It has expanded its operations to international markets like Vietnam.
Who are the competitors of Vaishali Pharma?
Vaishali Pharma major competitors are Mercury Laboratories, Denis Chem Lab, Makers Laboratories, Concord Drugs, Amwill Health Care, Curis Lifesciences, Bharat Immunological. Market Cap of Vaishali Pharma is ₹97 Crs. While the median market cap of its peers are ₹89 Crs.
Is Vaishali Pharma financially stable compared to its competitors?
Vaishali Pharma seems to be less financially stable compared to its competitors. Altman Z score of Vaishali Pharma is 3.06 and is ranked 6 out of its 8 competitors.
Does Vaishali Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Vaishali Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Vaishali Pharma allocated its funds?
Companies resources are allocated to majorly unproductive assets like Short Term Loans & Advances
How strong is Vaishali Pharma balance sheet?
Balance sheet of Vaishali Pharma is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Vaishali Pharma improving?
Yes, profit is increasing. The profit of Vaishali Pharma is ₹4.03 Crs for TTM, ₹0.82 Crs for Mar 2025 and ₹0.72 Crs for Mar 2024.
Is the debt of Vaishali Pharma increasing or decreasing?
Yes, The net debt of Vaishali Pharma is increasing. Latest net debt of Vaishali Pharma is ₹14.05 Crs as of Sep-25. This is greater than Mar-25 when it was ₹8.15 Crs.
Is Vaishali Pharma stock expensive?
Vaishali Pharma is not expensive. Latest PE of Vaishali Pharma is 24.04, while 3 year average PE is 121. Also latest EV/EBITDA of Vaishali Pharma is 26.99 while 3yr average is 122.
Has the share price of Vaishali Pharma grown faster than its competition?
Vaishali Pharma has given lower returns compared to its competitors. Vaishali Pharma has grown at ~-38.69% over the last 1yrs while peers have grown at a median rate of -17.0%
Is the promoter bullish about Vaishali Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Vaishali Pharma is 31.61% and last quarter promoter holding is 31.61%.
Are mutual funds buying/selling Vaishali Pharma?
There is Insufficient data to gauge this.